AgingResearch.NewsJoin free

Phase 1Recruiting

Tolerability of Ropeginterferon Alfa-2b Add-on to Ongoing Ruxolitinib Therapy in Myelofibrosis (RopeRux)

A Phase 1b Study of Safety, Tolerability of Ropeginterferon Alfa-2b Add-on to Ongoing Ruxolitinib Therapy in Myelofibrosis (RopeRux in Myelofibrosis)

Sponsor
University of Utah (Academic or other)
Enrolment
15 planned
Conditions
Myelofibrosis
Interventions
ropeginterferon alfa- 2b; Ruxolitinib
Ages
adults, older adults
Registry
NCT07521046

Full record on ClinicalTrials.gov

From the registry

The purpose of this clinical trial is to learn if the study drug ropeginterferon alfa- 2b added to, standard of care, ruxolitinib is safe and effective in treating patients with Myelofibrosis.

Primary outcomes

  • The frequency of adverse events (AEs) and serious adverse events (SAEs) characterized by type
  • The frequency of adverse events (AEs) and serious adverse events (SAEs) characterized by severity (as defined by the NIH CTCAE, version 6.0).
  • The frequency of adverse events (AEs) and serious adverse events (SAEs) characterized by seriousness.
  • The frequency of adverse events (AEs) and serious adverse events (SAEs) characterized by duration.

History

  1. Study completion expected

  2. Primary completion expected

  3. Started

  4. Last registry update

  5. Registered